SNOAHealthcare · Drug Manufacturers - Specialty & GenericSNOA Stock Forecast: Sonoma Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 1 Aug 2026 — in the weakest quartile.
SNOA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Sonoma Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (95): Smaller than most of the companies we track.
Momentum (7): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Sonoma Pharmaceuticals, Inc. — and when they’d sell — is the membership.
SNOA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SNOA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Sept 2023 | Ladenburg Thalmann | Initiates | Buy | $3.25 |
| 25 Nov 2020 | Benchmark | Initiates | Speculative Buy | — |
| 25 Nov 2020 | Maxim Group | Downgrade | Hold | — |
| 6 Mar 2018 | Maxim Group | Downgrade | Hold | — |
| 28 Dec 2017 | Benchmark | Initiates | Speculative Buy | — |
| 10 Nov 2017 | Maxim Group | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SNOA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Sonoma Pharmaceuticals, Inc. (SNOA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.6×
- Price / sales
- 0.3×
- Price / book
- 0.6×
- EV / EBITDA
- −1.6×
Cheaper than 80% of US stocks
Cheaper than 90% of US stocks
Cheaper than 81% of US stocks
Cheaper than 71% of US stocks
- Revenue growth (YoY)
- 48.1%
- Earnings growth (YoY)
- 48.1%
- Gross margin
- 39.2%
- Operating margin
- −6.3%
- Net margin
- −16.3%
Higher than 87% of US stocks
Higher than 77% of US stocks
Higher than 50% of US stocks
Higher than 28% of US stocks
Higher than 17% of US stocks
- Return on equity
- −84.6%
- Return on assets
- −11.1%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SNOA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNOA appears on the weeks it earns a place.
Frequently asked questions about SNOA stock
How does Ticker Nerd's model rank SNOA?
As at 1 Aug 2026, Sonoma Pharmaceuticals, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).
What is the SNOA stock forecast for 2030?
No analyst covering Sonoma Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNOA are extrapolating price history, which says nothing about the business.
How has SNOA stock performed over the past year?
Sonoma Pharmaceuticals, Inc. returned -62.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Sonoma Pharmaceuticals, Inc. do?
Sonoma Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing healing solutions for dermatological conditions and advanced wound care.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing healing solutions for dermatological conditions and advanced wound care. The primary purpose of this entity is to create non-toxic therapies that safely reduce infections and inflammation, accelerating the body's natural healing processes. Its product portfolio includes a range of topical anti-infective treatments and skin care solutions tailored for various fields, including dermatology, wound care, eye care, and animal health. Sonoma's formulations commonly feature hypochlorous acid, an element known for its antimicrobial and soothing properties. Significantly impacting the healthcare and pharmaceutical sectors, Sonoma Pharmaceuticals addresses critical needs in infection management and chronic wound therapy. The company’s innovations are particularly beneficial in hospital settings, outpatient clinics, and home care, offering versatile treatment options for both human and animal patients. Headquartered in Boulder, Colorado, the company's reach extends internationally, underscoring its role as a key player in improving patient outcomes through scientifically-backed therapeutic products.
CEO Ms. Amy M. Trombly Esq., J.D. · 10 employees · United States · https://sonomapharma.com